Close Menu

NEW YORK – The Foundation for Innovative New Diagnostics announced on Thursday it has signed a $14.5 million deal with Unitaid to evaluate using next-generation sequencing for diagnosing drug-resistant tuberculosis in low- and middle-income nations.

Over three years, starting in October, the project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa. The project, FIND said, will enable the introduction and adoption of targeted NGS technology for affordable, scalable, and rapid TB drug-susceptibility testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.